Blacher J - Search Results

1

Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients.

Blacher J, Asmar R, Djane S, London GM, Safar ME. Blacher J, et al. Hypertension. 1999 May;33(5):1111-7. doi: 10.1161/01.hyp.33.5.1111. Hypertension. 1999. PMID: 10334796

2

Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease.

Montalescot G, Ankri A, Chadefaux-Vekemans B, Blacher J, Philippe F, Drobinski G, Benzidia R, Kamoun P, Thomas D. Montalescot G, et al. Among authors: blacher j. Int J Cardiol. 1997 Aug 8;60(3):295-300. doi: 10.1016/s0167-5273(97)00099-5. Int J Cardiol. 1997. PMID: 9261641

3

[Conn's syndrome. Study of systemic cardiovascular hemodynamics after medical treatment with spironolactone and after surgical treatment].

Amah G, Blacher J, Girerd X, Kheder A, Ben Maiz H, Safar M. Amah G, et al. Among authors: blacher j. Presse Med. 1997 Oct 4;26(29):1372-7. Presse Med. 1997. PMID: 9404344 Clinical Trial. French.

4

Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension.

Blacher J, Amah G, Girerd X, Kheder A, Ben Mais H, London GM, Safar ME. Blacher J, et al. Am J Hypertens. 1997 Dec;10(12 Pt 1):1326-34. doi: 10.1016/s0895-7061(97)00301-4. Am J Hypertens. 1997. PMID: 9443767

5

Endothelin and cardiovascular remodelling in end-stage renal disease.

Demuth K, Blacher J, Guerin AP, Benoit MO, Moatti N, Safar ME, London GM. Demuth K, et al. Among authors: blacher j. Nephrol Dial Transplant. 1998 Feb;13(2):375-83. doi: 10.1093/oxfordjournals.ndt.a027833. Nephrol Dial Transplant. 1998. PMID: 9509449

6

Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease.

Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM. Blacher J, et al. Arterioscler Thromb Vasc Biol. 1998 Apr;18(4):535-41. doi: 10.1161/01.atv.18.4.535. Arterioscler Thromb Vasc Biol. 1998. PMID: 9555858

7

Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease.

Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM. Blacher J, et al. Hypertension. 1998 Sep;32(3):570-4. doi: 10.1161/01.hyp.32.3.570. Hypertension. 1998. PMID: 9740628

8

[Arterial hypertension, non-drug treatment and cardiovascular risk].

Blacher J, Tartiere JM, Amah G, Campa P, Raison J, Safar M. Blacher J, et al. Ann Cardiol Angeiol (Paris). 1998 Feb;47(2):81-5. Ann Cardiol Angeiol (Paris). 1998. PMID: 9772933 French.

9

[Conn adenoma manifesting as reversible tetraparesis and rhabdomyolysis].

Mourad JJ, Milliez P, Blacher J, Safar M, Girerd X. Mourad JJ, et al. Among authors: blacher j. Rev Med Interne. 1998 Mar;19(3):203-5. doi: 10.1016/s0248-8663(97)80722-9. Rev Med Interne. 1998. PMID: 9775143 French.

10

Increased arterial distensibility in postmenopausal hypertensive women with and without hormone replacement therapy after acute administration of the ACE inhibitor moexipril.

Blacher J, Raison J, Amah G, Schiemann AL, Stimpel M, Safar ME. Blacher J, et al. Cardiovasc Drugs Ther. 1998 Sep;12(4):409-14. doi: 10.1023/a:1007733103730. Cardiovasc Drugs Ther. 1998. PMID: 9825188 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results